Summit X LLC’s NanoViricides NNVC Stock Holding History

Summit X LLC’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-500	Closed	-$2K	–	240
2019 Q2	$2K	Hold	500	–	–	﹤0.01%	236
2019 Q1	$3K	Buy	+500	New	+$3.26K	﹤0.01%	243

Other funds holding NNVC

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Summit X LLC's NNVC Position: Q3 2019 in Review

Summit X LLC sold out of NanoViricides (NNVC) in Q3 2019, closing a stake of 500 shares — an estimated $2K sold.

Summit X LLC first reported a position in NNVC in Q1 2019 and held it in 2 quarters. The position peaked at $3K in Q1 2019. 17 funds tracked by Wall St. Rank hold NNVC as of Q3 2019.

Summit X LLC reported no remaining NanoViricides position as of Q3 2019 after selling out during the quarter.
Summit X LLC sold 500 NanoViricides shares in Q3 2019, an estimated $2K.
Summit X LLC first reported a position in NanoViricides in Q1 2019 and held it in 2 quarters.
Summit X LLC's NanoViricides position peaked at $3K in Q1 2019.
17 funds tracked by Wall St. Rank held NanoViricides as of Q3 2019.

Based on Summit X LLC's 13F filing for Q3 2019, filed 15 Oct 2019.